649 related articles for article (PubMed ID: 28296582)
21. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
22. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Lukka H; Hayter C; Julian JA; Warde P; Morris WJ; Gospodarowicz M; Levine M; Sathya J; Choo R; Prichard H; Brundage M; Kwan W
J Clin Oncol; 2005 Sep; 23(25):6132-8. PubMed ID: 16135479
[TBL] [Abstract][Full Text] [Related]
24. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
Arcangeli G; Saracino B; Arcangeli S; Gomellini S; Petrongari MG; Sanguineti G; Strigari L
J Clin Oncol; 2017 Jun; 35(17):1891-1897. PubMed ID: 28355113
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
26. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.
Yeoh EE; Holloway RH; Fraser RJ; Botten RJ; Di Matteo AC; Butters J; Weerasinghe S; Abeysinghe P
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1072-83. PubMed ID: 16965866
[TBL] [Abstract][Full Text] [Related]
28. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer.
Lee TH; Pyo H; Yoo GS; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Bae BK; Park W
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):333-341. PubMed ID: 38477380
[TBL] [Abstract][Full Text] [Related]
30. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
Leborgne F; Fowler J; Leborgne JH; Mezzera J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
[TBL] [Abstract][Full Text] [Related]
31. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
32. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T
J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048
[TBL] [Abstract][Full Text] [Related]
33. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.
Yeoh EE; Botten RJ; Butters J; Di Matteo AC; Holloway RH; Fowler J
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1271-8. PubMed ID: 20934277
[TBL] [Abstract][Full Text] [Related]
35. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
Buyyounouski MK; Pugh SL; Chen RC; Mann MJ; Kudchadker RJ; Konski AA; Mian OY; Michalski JM; Vigneault E; Valicenti RK; Barkati M; Lawton CAF; Potters L; Monitto DC; Kittel JA; Schroeder TM; Hannan R; Duncan CE; Rodgers JP; Feng F; Sandler HM
JAMA Oncol; 2024 May; 10(5):584-591. PubMed ID: 38483412
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
38. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation.
Ha B; Cho KH; Lee KH; Joung JY; Kim YJ; Lee SU; Kim H; Suh YG; Moon SH; Lim YK; Jeong JH; Kim H; Park WS; Kim SH
Radiat Oncol; 2019 Jan; 14(1):4. PubMed ID: 30630500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
